**A prediction model for major adverse cardiovascular events (MACE) in patients with coronavirus disease 2019 (COVID-19)**

Dong Huang¹, Huan Yang¹, He Yu¹, Ting Wang¹, Zhu Chen², Rong Yao³,⁴* and Zongan Liang¹*

**Abstract**

**Background:** Emerging evidence shows that cardiovascular injuries and events in coronavirus disease 2019 (COVID-19) should be considered. The current study was conducted to develop an early prediction model for major adverse cardiovascular events (MACE) during hospitalizations of COVID-19 patients.

**Methods:** This was a retrospective, multicenter, observational study. Hospitalized COVID-19 patients from Wuhan city, Hubei Province and Sichuan Province, China, between January 14 and March 9, 2020, were randomly divided into a training set (70% of patients) and a testing set (30%). All baseline data were recorded at admission or within 24 h after admission to hospitals. The primary outcome was MACE during hospitalization, including nonfatal myocardial infarction, nonfatal stroke and cardiovascular death. The risk factors were selected by LASSO regression and multivariate logistic regression analysis. The nomogram was assessed by calibration curve and decision curve analysis (DCA).

**Results:** Ultimately, 1206 adult COVID-19 patients were included. In the training set, 48 (5.7%) patients eventually developed MACE. Six factors associated with MACE were included in the nomogram: age, PaO₂/FiO₂ under 300, unconsciousness, lymphocyte counts, neutrophil counts and blood urea nitrogen. The C indices were 0.93 (95% CI 0.90, 0.97) in the training set and 0.81 (95% CI 0.70, 0.93) in the testing set. The calibration curve and DCA demonstrated the good performance of the nomogram.

**Conclusions:** We developed and validated a nomogram to predict the development of MACE in hospitalized COVID-19 patients. More prospective multicenter studies are needed to confirm our results.

**Keywords:** COVID-19, MACE, Risk factors, Nomogram

**Background**

The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, has been widely recognized and reported since December 2019 [1]. The World Health Organization (WHO) made the assessment that COVID-19 could be characterized as a pandemic in March 2020 [2]. It is still sweeping the globe [3]. The pathogenic mechanism and epidemiological and clinical characteristics of COVID-19 seem not to be very different from those of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) [4]. Therefore, COVID-19 is often considered as a primary respiratory infectious disease and viral pneumonia. However, emerging evidence shows that extrapulmonary manifestations, complications and multiorgan injuries should also be considered [5].

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
It was reported that the incidences of severe cardiovascular events, such as stroke and acute myocardial infarction, among all COVID-19 patients were 2.5% and 1.1%, respectively [6]. Moreover, they are also significant contributors to the poor prognosis of severe COVID-19 patients. In patients with COVID-19 and ST-segment elevation myocardial infarction (STEMI), 18% of them required mechanical ventilation, 17% required cardiac resuscitation, and 11% eventually died [7]. Another study reported that the mortality of COVID-19 patients with ischemic stroke was approximately 30% [8].

There is little available information about the risk factors and prediction models for major adverse cardiovascular events (MACE), which consist of myocardial infarction, stroke, and cardiovascular death. Li et al. [8] reported that older COVID-19 patients with hypertension, diabetes, and high levels of C reactive protein (CRP) and D-dimer were prone to acute cerebrovascular disease. Tan et al. [9] conducted a systemic review and found that elevated D-dimer and fibrinogen, as well as detected antiphospholipid antibodies, were associated with acute ischemic stroke in patients with COVID-19. However, these above conclusions are not identical and need more evaluation because most previous studies were single-center, had limited sample sizes, did not have control groups, or lacked adjustment for confounding factors.

Considering that the severity of disease among different COVID-19 patients is highly heterogeneous, ranging from asymptomatic infection or mild disease to critical illness with multiple organ injuries, early prediction, detection and diagnosis of MACE are of great importance to optimize therapies, which might also improve the prognosis of COVID-19 patients. The current study was conducted to identify related risk factors and to develop and validate an early prediction model for MACE during the hospitalization of COVID-19 patients.

**Methods**

**Study design, participants and data collection**

This retrospective, multicenter, observational study was conducted on hospitalized patients from two major COVID-19 designated hospitals (Wuhan Red Cross Hospital and People’s Hospital of Wuhan University) in Wuhan city, Hubei Province, and 36 COVID-19 designated hospitals, including university teaching hospitals and regional hospitals, in Sichuan Province, China, between January 14 and March 9, 2020. It was conducted in accordance with the amended Declaration of Helsinki and approved by the West China Hospital of Sichuan University Biomedical Research Ethics Committee (No. 2020-272). Written informed consent was waived due to its retrospective observational design. The development and validation of the prediction model were performed in accordance with the TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis) statement [10].

For the calculation of sample size, it was estimated that 4–8 variables would eventually be included in the prediction model. In most cases, the events per variable (EPV) should exceed 10 to ensure the accuracy and efficacy of the variables [11]. Therefore, 40–80 patients with MACE were needed. However, up to 10% of patients might drop out or have incomplete clinical data. As a result, 44–88 patients with MACE are warranted. Finally, the incidence of MACE in all COVID-19 patients was less than 10% in previous studies. Thus, the required sample size of COVID-19 patients was estimated to be at least 440–880.

All patients enrolled in this study had laboratory-confirmed COVID-19 according to the WHO interim guidance, which was defined as a positive result for the nucleic acid of SARS-CoV-2 by real-time reverse-transcription polymerase chain reaction (RT–PCR) [12]. The exclusion criteria were as follows: (1) under 18 years old; (2) being pregnant; (3) died or discharged within 24 h after admission; (4) incomplete clinical data; and (5) recovering from cardiac arrest or cardiopulmonary resuscitation.

The selection of patients was independently completed by two trained clinicians. Any disagreement was resolved by team discussion until a consensus was reached. All included patients were randomly divided into a training set (70% of patients) and a testing set (30%). The training set was applied to develop a prediction model, and the testing set was used to validate the performance of the model. The clinical baseline characteristics between the two sets were compared to ensure similarity or nonsignificant differences.

All clinical data, including demographic characteristics, symptoms, basic vital signs, comorbidities, chest computed tomography (CT) results and laboratory examinations, were collected from the electronic medical records and anonymized. The baseline data were recorded at admission or within 24 h after admission to hospitals. Two experienced doctors independently reviewed the medical records and completed the data collection. Any disagreement was resolved by a third doctor or team discussion until a consensus was reached.

**Study outcomes**

The primary outcome was MACE during hospitalization, including nonfatal myocardial infarction, nonfatal stroke and cardiovascular death. This triple composite endpoint is commonly used in studies to investigate the cardiovascular risks of diabetes and the effects of related drugs [13]. It has been used in various cardiovascular studies in recent years.
Specifically, acute myocardial infarction (AMI) was defined as the detection of elevated cardiac troponin with at least 1 value above the 99th percentile upper reference limit and at least one of the following: symptoms of myocardial ischemia; new ischemic electrocardiograph (ECG) changes; imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; and identification of a coronary thrombus by angiography or autopsy [14]. Stroke was diagnosed by its clinical manifestations and confirmed via CT or magnetic resonance imaging (MRI) [15]. Cardiovascular death was defined as death with obvious cardiovascular causes or not definitely attributable to non-cardiovascular causes, including but not limited to fatal myocardial infarction, fatal stroke, sudden death, death caused by cardiogenic shock, death related to cardiovascular procedures and death from other cardiovascular causes.

**Statistical analysis**

Data were analyzed with IBM SPSS Statistics version 23.0 and R software 4.0.2. Continuous variables are presented as the mean (standard deviation, SD) or median (interquartile range, IQR) according to their distribution, as determined by the Kolmogorov–Smirnov normality test and Bartlett’s test for homogeneity of variance. Categorical variables are shown with counts and percentages. Means for continuous variables were compared by using two-tailed independent Student’s t-tests when the data were normally distributed; if not, the Mann–Whitney U test was used. Proportions for categorical variables were compared with the $\chi^2$ test or Fisher’s exact test.

We used multiple imputation (MI), which was performed by using Bayesian methods in SPSS, to minimize bias due to the retrospective design. It was applied to account for missing data if the missing values were under 20%. The variables with a missing rate of above 20% were excluded. The risk factors were preliminarily selected by LASSO (least absolute shrinkage and selection operator) regression analysis. It was used to minimize the potential collinearity or overfitting of variables measured from the same patient. The LASSO regression model could penalize the regression coefficients of variables through the parameter $\lambda$. With the largest penalties and minimum $\lambda$, the estimates of weak factors could shrink toward zero and be eliminated. Therefore, the final model only included the strongest predictors. The glmnet package in R was used to perform the LASSO regression.

The patients in the training set were divided into two groups according to the presence or absence of MACE. Variables with $P<0.10$ were included in the univariate and multivariate logistic regression analyses to identify independent risk factors for MACE. The fitness of multivariate logistic regression model was tested by using a Hosmer–Lemeshow (H–L) test. The interactions and multicollinearity among the independent risk factors were also examined. A variance inflation factors (VIF) $>10$ was considered indicative of multicollinearity. We used odds ratios (ORs) and 95% confidence intervals (95% CIs) to evaluate the risk factors.

The prediction model was established through the rms package in R based on the results of LASSO regression and multivariate logistic regression. The goodness of fit of the prediction model was evaluated via the concordance index (C index) with the 95% CIs [16]. Then, a nomogram was visually established based on the prediction model with the highest C index [17]. The nomogram was also assessed by calibration curve and decision curve analysis (DCA) in the training set (internal validation) and testing set (external validation) [18, 19]. After that, subgroup analysis in terms of the regions where COVID-19 patients were from (Wuhan or Sichuan) was also performed to test the performance and accuracy of the model further in different COVID-19 patients. Statistical significance was defined as $P<0.05$.

**Results**

**Baseline patient characteristics**

A total of 1240 patients confirmed to have COVID-19 were included in this study. Finally, 34 of them were excluded after applying the exclusion criteria. Among the remaining 1206 patients, 844 patients (70% of all patients; 633 patients from Wuhan and 211 patients from Sichuan) were randomized to the training set, and 362 patients (30% of all patients; 265 patients from Wuhan and 97 patients from Sichuan) were included in the testing set. The detailed selection of patients is shown in Fig. 1. The clinical baseline characteristics of the training and testing sets are compared in Additional file 1: Table S1. There were a few significant differences in the respiratory rate ($P=0.022$), chronic neural disease ($P=0.008$), PT ($P=0.042$) and Na ($P=0.018$). Other characteristics were not significantly different between the two sets. Thus, there was no significant bias when splitting the two groups.

In the training set, 48 (5.7%) patients eventually developed MACE. Among them, 8 (0.9%) patients had AMI, and 9 (1%) patients developed stroke. Finally, 38 (4.5%) patients were diagnosed with cardiovascular death. Compared with patients without MACE, the MACE group had a higher proportion of male patients (64.6% vs. 46.9%, $P=0.017$), median age (72.5 vs. 54 years, $P<0.001$), respiratory rate (21 vs. 20 breath/min, $P=0.005$), rate of unconscious patients (16.7% vs. 0.3%, $P<0.001$), more patients whose PaO$_2$/FiO$_2$ (arterial partial pressure of oxygen/fraction of inspiration oxygen) was less than 300 (35.4% vs. 10.6%, $P<0.001$),
more comorbidities (chronic heart disease: 22.9% vs. 8.3%, \( P = 0.002 \); chronic kidney disease: 10.4% vs. 1.3%, \( P = 0.001 \)), etc. Some significant differences in laboratory examination results were also observed between patients with and without MACE. The MACE group had higher neutrophil counts (6.56 × 10^9/L vs. 3.47 × 10^9/L, \( P < 0.001 \)), D-dimer (2.29 mg/L vs. 0.57 mg/L, \( P < 0.001 \)), and blood urea nitrogen (BUN, 7.04 mmol/L vs. 4.32 mmol/L, \( P < 0.001 \)) but lower lymphocyte counts (0.54 × 10^9/L vs. 1.19 × 10^9/L, \( P < 0.001 \)) and albumin (35.3 g/L vs. 39.1 g/L, \( P < 0.001 \)). Detailed comparisons of the baseline characteristics are shown in Table 1.

**Development of a prediction model for MACE**

The above eighty-five variables measured at admission or within 24 h after admission to hospitals were included in the LASSO regression selection. Finally, the LASSO regression model identified 3 variables that were significant predictors of MACE in COVID-19 patients, including unconsciousness, neutrophil counts and BUN (Additional file 1: Fig. S1).

The factors with \( P < 0.1 \) in Table 1 were included in the univariate and multivariate logistic regression analysis model. The result of H-L test was \( P = 0.333 \), suggesting good fitness of the multivariate logistic regression analysis model. There were no significant
### Table 1 Comparisons of clinical characteristics between patients with MACE and patients without MACE in training set

| Variables                        | Overall (n = 844) | With MACE (n = 48) | Without MACE (n = 796) | P value |
|----------------------------------|-------------------|--------------------|------------------------|---------|
| **Demographic characteristics**  |                   |                    |                        |         |
| Sex (male)                       | 404 (47.9)        | 31 (64.6)          | 373 (46.9)             | 0.017   |
| Age, years                       | 55 (41.66)        | 72.5 (64.81)       | 54 (39.65)             | < 0.001 |
| History of alcohol use           | 181 (21.4)        | 9 (18.8)           | 172 (21.6)             | 0.639   |
| Smoking history                  | 180 (21.3)        | 11 (22.9)          | 169 (21.2)             | 0.782   |
| **Vital signs on admission**     |                   |                    |                        |         |
| Temperature (°C)                 | 36.7 (36.4, 37)   | 36.6 (36.3, 36.9)  | 36.7 (36.4, 37.1)      | 0.657   |
| Heart rate (beat/min)            | 85 (78.96)        | 84 (78.100)        | 86 (78.96)             | 0.785   |
| Respiratory rate (breath/min)    | 20 (19.21)        | 21 (19.28)         | 20 (19.20)             | 0.005   |
| Systolic pressure (mmHg)         | 128 (119, 140)    | 130 (120, 143)     | 128 (119, 140)         | 0.494   |
| Diastolic pressure (mmHg)        | 79 (70, 85)       | 76 (68, 83)        | 79 (71, 85)            | 0.022   |
| PaO2/FiO2 under 300              | 101 (12)          | 17 (35.4)          | 84 (10.6)              | < 0.001 |
| Glasgow coma scale               | 15 (15, 15)       | 15 (14, 15)        | 15 (15, 15)            | < 0.001 |
| **Symptoms and Signs**           |                   |                    |                        |         |
| Fever                            | 559 (66.2)        | 35 (72.9)          | 524 (65.8)             | 0.313   |
| Cough                            | 536 (63.5)        | 31 (64.6)          | 505 (63.4)             | 0.873   |
| Hemoptysis                       | 26 (3.1)          | 0 (0)              | 26 (3.3)               | 0.4     |
| Short of breath/dyspnea          | 176 (20.9)        | 26 (54.2)          | 150 (18.8)             | < 0.001 |
| Weakness/fatigue                 | 307 (36.4)        | 26 (54.2)          | 281 (35.3)             | 0.008   |
| Sore throat/pharyngalgia         | 59 (7)            | 1 (2.1)            | 58 (7.3)               | 0.279   |
| Rhinorrhea                       | 18 (2.1)          | 0 (0)              | 18 (2.3)               | 0.59    |
| Wheeze                           | 94 (11.1)         | 12 (25)            | 82 (10.3)              | 0.002   |
| Stuffy nose                      | 13 (1.5)          | 0 (0)              | 13 (1.6)               | 1.00    |
| Chest pain/distress              | 192 (22.7)        | 14 (29.2)          | 178 (22.4)             | 0.275   |
| Muscle ache/myalgia              | 84 (10)           | 4 (8.3)            | 80 (10.1)              | 0.891   |
| Arthralgia                       | 15 (1.8)          | 2 (4.2)            | 13 (1.6)               | 0.208   |
| Headache                         | 54 (6.4)          | 1 (2.1)            | 53 (6.7)               | 0.34    |
| Unconsciousness                  | 10 (1.2)          | 8 (16.7)           | 2 (0.3)                | < 0.001 |
| Stomachache                      | 18 (2.1)          | 2 (4.2)            | 16 (2)                 | 0.624   |
| Nausea/vomiting                  | 35 (4.1)          | 2 (4.2)            | 33 (4.1)               | 1.00    |
| Diarrhea                         | 107 (12.7)        | 4 (8.3)            | 103 (12.9)             | 0.352   |
| **Comorbidities**                |                   |                    |                        |         |
| Chronic heart disease            | 77 (9.1)          | 11 (22.9)          | 66 (8.3)               | 0.002   |
| Asthma                           | 5 (0.6)           | 0 (0)              | 5 (0.6)                | 1.00    |
| COPD                             | 22 (2.6)          | 4 (8.3)            | 18 (2.3)               | 0.036   |
| Chronic kidney disease           | 15 (1.8)          | 5 (10.4)           | 10 (1.3)               | 0.001   |
| Chronic liver disease            | 53 (6.3)          | 3 (6.3)            | 50 (6.3)               | 1.00    |
| Chronic neural disease           | 7 (0.8)           | 2 (4.2)            | 5 (0.6)                | 0.055   |
| Cancer                           | 26 (3.1)          | 5 (10.4)           | 21 (2.6)               | 0.009   |
| Diabetes mellitus                | 120 (14.2)        | 6 (12.5)           | 114 (14.3)             | 0.726   |
| Autoimmune disease               | 7 (0.8)           | 0 (0)              | 7 (0.9)                | 1.00    |
| Dementia                         | 11 (1.3)          | 2 (4.2)            | 9 (1.1)                | 0.126   |
| Hematological disease            | 24 (2.8)          | 1 (2.1)            | 23 (2.9)               | 1.00    |
| Stroke history                   | 15 (1.8)          | 2 (4.2)            | 13 (1.6)               | 0.208   |
| Hypertension                     | 232 (27.5)        | 24 (50)            | 208 (26.1)             | < 0.001 |
| **Laboratory examinations**      |                   |                    |                        |         |
| White blood cell, × 10⁹/L        | 5.5 (4.3, 7.04)   | 7.8 (5.5, 12.5)    | 5.5 (4.3, 6.88)        | < 0.001 |
| Hemoglobin, g/L                  | 128 (118, 139)    | 123.5 (108, 141)   | 128 (119, 139)         | 0.07    |
| Platelet counts, × 10⁹/L         | 206 (162, 259)    | 200 (137, 261)     | 206 (163, 259)         | 0.103   |
### Table 1 (continued)

| Variables                              | Overall (n = 844) | With MACE (n = 48) | Without MACE (n = 796) | P value |
|-----------------------------------------|-------------------|--------------------|------------------------|---------|
| Lymphocyte counts, $\times 10^{9}$/L    | 1.19(0.89,1.62)   | 0.54(0.42,1.15)    | 1.19(0.92,1.65)        | < 0.001 |
| Neutrophil counts, $\times 10^{9}$/L    | 3.57(2.61,4.86)   | 6.56(4.15,11.18)   | 3.47(2.56,4.63)        | < 0.001 |
| Eosinophils, $\times 10^{9}$/L          | 0.03(0.01,0.08)   | 0.01(0.01,0.04)    | 0.03(0.01,0.09)        | 0.001   |
| Basophils, $\times 10^{5}$/L            | 0.01(0.01,0.03)   | 0.01(0.01,0.03)    | 0.01(0.01,0.03)        | 0.445   |
| Monocyte count, $\times 10^{9}$/L       | 0.43(0.32,0.55)   | 0.40(0.29,0.50)    | 0.43(0.32,0.56)        | 0.381   |
| Hematocrit (%)                          | 0.38(0.35,0.41)   | 0.36(0.32,0.40)    | 0.38(0.35,0.41)        | 0.024   |
| D-dimer, mg/L                           | 0.60(0.37,1.05)   | 2.29(0.79,1.77)    | 0.57(0.36,0.88)        | < 0.001 |
| Fibrinogen, g/L                         | 3.62(2.85,4.32)   | 4.83(3.13,6.3)     | 3.56(2.85,4.24)        | 0.001   |
| APTT, s                                 | 28(26.3,29.7)     | 28.5(27.4,31.8)    | 27.8(26.2,29.5)        | 0.007   |
| PT, s                                   | 12(11.5,12.5)     | 12.8(12,14.1)      | 12(11.4,12.4)          | < 0.001 |
| INR                                     | 1.03(0.97,1.06)   | 1.1(1.03,1.19)     | 1.03(0.97,1.05)        | < 0.001 |
| Total bilirubin, μ mol/L                | 10.28(13.1)       | 10.69(6.19,2.19)   | 10.27(9.12.8)          | 0.001   |
| Direct bilirubin, μ mol/L               | 3.2(2,4,4.4)      | 4.45(3.3,8.8)      | 3.3(2,4,2)             | < 0.001 |
| Indirect bilirubin, μ mol/L             | 6(6.7,5)          | 6.9(6.9,9.32)      | 6.9(5.9,7.5)           | 0.085   |
| ALT, IU/L                               | 24(17,36)         | 24(18,40)          | 24(17,36)              | 0.92    |
| AST, IU/L                               | 24(20.33)         | 29(22.46)          | 24(20,32)              | 0.006   |
| Total protein, g/L                      | 64.66(60.1,68.7)  | 60.55(66,68.9)     | 64(60.1,68.9)          | < 0.001 |
| Albumin, g/L                            | 39(35.9,42.2)     | 35.3(31.39,1)      | 39.1(36.2,42.4)        | < 0.001 |
| Globulin, g/L                           | 25(22.6,28.1)     | 25.2(22,27.6)      | 25.2(22.6,28.2)        | 0.861   |
| Triglyceride, mmol/L                    | 1.21(1.04,1.51)   | 1.21(1.12,1.65)    | 1.21(1.03,1.50)        | 0.163   |
| Cholesterol, mmol/L                     | 4.03(3.62,4.40)   | 4.04(3.35,4.11)    | 4.04(3.63,4.4)         | 0.117   |
| HDL, mmol/L                             | 1(0.92,1.16)      | 0.94(0.75,1.03)    | 1.03(0.94,1.16)        | 0.001   |
| LDL, mmol/L                             | 2.41(2.12,2.65)   | 2.3(1.94,2.59)     | 2.41(1.4,2.68)         | 0.306   |
| CKMB, U/L                               | 1.31(0.99,2.20)   | 1.31(1.1,1.84)     | 1.31(0.97,1.75)        | 0.001   |
| Glucose, mmol/L                         | 5.61(5.01,6.45)   | 6.14(5.59,8.17)    | 5.59(4.98,6.38)        | < 0.001 |
| Na, mmol/L                              | 141(139,143)      | 140(138,144)       | 141(139,143)           | 0.908   |
| K, mmol/L                               | 4.68(4.19,4.98)   | 4.18(3.95,4.62)    | 3.95(3.66,4.17)        | < 0.001 |
| Ca, mmol/L                              | 2.18(2.10,2.27)   | 2.12(2.12,2.18)    | 2.18(2.10,2.28)        | < 0.001 |
| Mg, mmol/L                              | 0.85(0.81,0.88)   | 0.89(0.81,0.96)    | 0.85(0.81,0.88)        | 0.248   |
| BUN, mmol/L                             | 4.32(3.60,5.41)   | 7.04(4.32,12.3)    | 4.32(3.56,5.24)        | < 0.001 |
| Creatinine, μ mol/L                     | 62(52.7)          | 66(59.5,125.5)     | 62(50,70)              | 0.001   |
| Uric acid, umol/L                       | 260(215,316)      | 266(218,399)       | 260(214,314)           | 0.271   |
| Myoglobin, g/L                          | 32.3(31.2,33.8)   | 49.4(32.3,172)     | 32.3(30.4,32.3)        | < 0.001 |
| C-reactive protein, mg/L                | 10.6(7.15,0.07)   | 17.2(10.17)        | 10.5(9.4,12.14)        | < 0.001 |
| Procalcitonin, μ g/L                    | 0.05(0.04,0.06)   | 0.11(0.05,0.52)    | 0.05(0.04,0.05)        | < 0.001 |

**Chest CT scan images**

| Abnormal lobes                          | 4(1,5)            | 0(0.5)             | 4(1,5)                 | < 0.001 |
| Consolidation                           | 135(16)           | 4(8.3)             | 131(16.5)              | 0.136   |
| Ground-glass opacity                    | 662(78.4)         | 46(95.8)           | 616(77)                | 0.033   |
| Paving                                  | 5(0.6)            | 0(0)               | 5(0.6)                 | 1.00    |
| Fibrotic                                | 206(24.4)         | 5(10.4)            | 201(25.3)              | 0.02    |
| Effusion                                | 39(4.6)           | 4(8.3)             | 35(4.4)                | 0.364   |

Data are shown as median with interquartile range (IQR) for continuous variables or number with percentage for categorical variables.

**MACE major adverse cardiovascular events, n numbers, PaO2 arterial partial pressure of oxygen, FiO2 fraction of inspiration oxygen, COPD chronic obstructive pulmonary disease, APTT activated partial thromboplastin time, PT prothrombin time, INR international normalized ratio, ALT alanine aminotransferase, AST aspartate aminotransferase, HDL high density lipoprotein, LDL low density lipoprotein, CKMB creatine kinase-MB, Na sodium, K potassium, Ca calcium, Mg magnesium, BUN blood urea nitrogen, CT computed tomography.**
interactions among these factors. All VIF values were around 1, indicating the absence of multicollinearity. The Cox&Snell $R^2$ and Nagelkerke $R^2$ value was 0.240 and 0.679, respectively. Finally, we found 6 factors that were independently associated with MACE: age, $\text{PaO}_2/\text{FiO}_2$ under 300, unconsciousness, lymphocyte counts, neutrophil counts and BUN. The detailed ORs and 95% CIs were shown in Table 2.

As a result, these six factors were included in the prediction model, as described in Fig. 2. Each predictive factor was assigned a single score, which is presented on the top line of the nomogram. The total score for each patient is the sum of each single score. At the bottom of the nomogram, the probabilities of MACE during hospitalization in patients with COVID-19 were predicted in terms of the total scores.

### Table 2: The independent risk factors associated with MACE in multivariate logistic regression analysis in training set

| Variables                     | OR  | 95% CI       | P value |
|-------------------------------|-----|--------------|---------|
| Age                           | 1.10| 1.06, 1.15   | <0.001  |
| $\text{PaO}_2/\text{FiO}_2$ under 300 | 8.83| 2.76, 28.24  | <0.001  |
| Unconsciousness               | 46.78| 2.99, 730.83 | 0.006   |
| Lymphocyte counts             | 0.13| 0.04, 0.41   | <0.001  |
| Neutrophil counts             | 1.17| 1.04, 1.32   | 0.011   |
| BUN                           | 1.11| 1.02, 1.21   | 0.021   |

MACE major adverse cardiovascular events, OR odds ratio, CI confidence interval, $\text{PaO}_2$ arterial partial pressure of oxygen, $\text{FiO}_2$ fraction of inspiration oxygen, BUN blood urea nitrogen

**Validation of the prediction model for MACE**

By using the bootstrap method, the C index was 0.93 (95% CI 0.90, 0.97) in the training set, which indicated that the predictive value was good. As shown in Fig. 3A, the calibration curve did not deviate from the reference line significantly. There was good consistency between the values predicted by the nomogram and the actual observed values in the training set. The adjusted C index was 0.93. To evaluate the clinical applicability of the prediction model, DCA was performed, as shown in Fig. 4A. DCA demonstrated that the nomogram had good overall net benefits within a wide range of threshold probabilities. The nomogram could improve patient outcomes in clinical practice.

In the testing set, 15 (4.1%) patients were diagnosed with MACE. Specifically, 6 (1.7%) patients developed AMI, 2 (0.6%) patients developed stroke, and 10 (2.8%) patients were diagnosed with cardiovascular death. The C index was 0.81 (95% CI 0.70, 0.93) in the testing set, which was lower than that in the training set. As shown in Fig. 3B, the calibration curve indicated good agreement between the estimated results and the actual results of MACE. The adjusted C index was 0.75. The prediction model had stability and external validity to some degree. Figure 4B shows the DCA of the nomogram in the testing set. Similarly, the net benefits within a wide range of threshold probabilities showed that the nomogram had positive impacts on patient outcomes.

In the subgroup analysis, a total of 57 (6.3%) COVID-19 patients had MACE (AMI: 11 [1.2%]; stroke: 9 [1.0%]; cardiovascular death: 45 [5.0%]), and the C index was 0.89 (95% CI 0.84, 0.94) in the Wuhan subgroup. The calibration curve and DCA are shown in
Additional file 1: Figs. S2 and S3 in the supplementary material. The adjusted C index was 0.88. In the Sichuan subgroup, 6 (1.9%) patients had MACE (AMI: 3 [1%]; stroke: 2 [0.6%]; cardiovascular death: 3 [1%]). The C index was 0.97 (95% CI 0.92, 1.02), and the adjusted C index was 0.96. The calibration curve and DCA are shown in Additional file 1: Figs. S4 and S5 in the supplementary material. The results of the subgroup analysis were similar to those of the overall analysis.

**Discussion**

In the present study, we included over 1200 confirmed adult COVID-19 patients from Wuhan, a relatively high prevalence area, and Sichuan, a relatively low prevalence area.
area, treated at the beginning of 2020 to ensure the accuracy and applicability of the results. The nomogram comprehensively included various aspects of COVID-19 pathophysiology, including demographic characteristics, symptoms, vital signs and laboratory results. Its performance and accuracy were satisfactory based on the C index, which varied from 0.814 to 0.970 in all sets and subgroups. The calibration curve and DCA verified its clinical value.

The pathophysiological mechanisms of cardiovascular injuries or events in COVID-19 are still uncertain thus far and have varied across previous studies. Limited data show that potential explanations include direct viral toxicity and myocyte injury through the angiotensin-converting enzyme 2 (ACE2) receptor in host cells, dysregulation of the renin–angiotensin–aldosterone system (RAAS), endothelial cell damage, immune-mediated cytokine storm syndrome or stress-related cardiomyopathy, a mismatch between oxygen supply and demand, hypercoagulable state and dysregulation of fibrinolysis and thrombosis [20–23]. Nevertheless, these different pathways and roles of various cytokines and other components in the development of cardiovascular events remain an area of active investigation.

Advanced age has been generally known as a risk factor for critical illness or a poor prognosis of COVID-19 in a series of prior studies [24, 25]. However, the other variables in the nomogram have been relatively less explored. We should be more cautious about using them in clinical practice. The presence of decreased \( \text{PaO}_2/\text{FiO}_2 \) and unconsciousness indicate that these patients are already seriously ill or critically ill at admission. As a result, their incidences of cardiovascular events, multiple organ injuries and other adverse clinical outcomes are all comparatively high. A systemic review showed that age (per 10 years increase OR 1.8, 95% CI 1.54–2.1; certainty of the evidence: high), hypoxemia (OR 5.46, 95% CI 2.05–14.53; certainty of the evidence: moderate), decreased lymphocytes (OR 3.57, 95% CI 2–6.67; certainty of the evidence: moderate), increased neutrophils (OR 6.78, 95% CI 3.07–14.97; certainty of the evidence: high) and high BUN (OR 10.56, 95% CI 6.76–16.48; certainty of the evidence: low) were all prognostic factors for mortality. Lymphocytes, neutrophils and BUN were additional predictive factors for severe COVID-19 [26]. SARS-CoV-2 has the potential to invade both the central and peripheral nervous systems. It enters the brain via the hematogenous route or the olfactory system. Severe neurological manifestations, including agitation, delirium, and coma, are probably due to hypoxic and metabolic abnormalities [27]. Additionally, two prior studies with large sample sizes revealed that in COVID-19 patients, unconsciousness (OR, 4.71; 95% CI 1.39–15.98) was an independent predictive factor of critical illness (admission to the intensive care unit or invasive ventilation or death) [28], and peripheral oxygen saturation under 92% (HR 2.12, CI 1.56–2.88) was associated with an increased risk of in-hospital mortality [29].

Previous preclinical and clinical studies have well explored the predictive and prognostic values of laboratory results, which agree with our results. Lymphocytopenia, which is caused by systemic inflammation and immunocompromised status, has been considered one of the most common clinical characteristics of COVID-19. Lymphocytes play a crucial role in the modulation of the systemic inflammatory response and atherosclerotic process. Furthermore, lymphocytopenia is related to accelerated atherosclerosis, acute coronary syndromes and a poor prognosis of patients [30]. It has been reported that a high neutrophil to lymphocyte ratio (NLR) has good sensitivity and specificity for a COVID-19 diagnosis in all patients admitted to hospitals [31]. Another meta-analysis of 17 articles with 3396 COVID-19 patients showed that a significant decrease in lymphocytes and increases in neutrophils and BUN were observed in severe COVID-19 patients compared with non-severe patients [32]. The impacts of BUN, a biomarker of kidney injury, on cardiovascular events are still unclear. In 2009 influenza A (H1N1) viral pneumonia, compared with patients without acute kidney injury (AKI), patients with AKI presented more marked cardiovascular, respiratory, and hematological dysfunction [33]. In COVID-19, AKI was a predictor of fatality (OR 14.63, 95% CI 9.94–21.51) and severe infection (OR 8.11, 95% CI 5.01–13.13). A higher level of serum BUN was also associated with a significant increase in fatality (mean difference, MD: 4.07 mmol/L, 95% CI 3.33–4.81) and severe infection (MD: 2.12 mmol/L, 95% CI 1.74–2.50) [34].

The development of MACE in COVID-19 patients has also been reported. Pareek et al. included 586 COVID-19-positive patients and found that higher respiratory rates, altered mental status, and higher troponin T could predict MACE, which was defined as a composite of myocardial infarction, stroke, new acute decompensated heart failure, venous thromboembolism, ventricular or atrial arrhythmia, pericardial effusion, or aborted cardiac arrest. The incidence of MACE in their cohort was 23.0% [35]. In another study from Henein et al., among the 748 patients included, 141 (19%) reached the set endpoint of MACE, a composite of in-hospital CV death, acute heart failure (AHF), acute myocarditis, arrhythmias, acute coronary syndromes (ACS), cardiocirculatory arrest, and pulmonary embolism (PE). In multivariate analysis, troponin and renal failure were good predictors [36]. In another cohort of 839 patients with COVID-19, 72 (9%) patients had MACE, defined as CV death, heart failure,
Thus, our conclusions remain useful for decision making development of MACE still exist in COVID-19 patients. The associations of these identified risk factors with could probably be decreased. However, we believe that We admit that the predictive accuracy of nomogram 19 patients now is significantly lower than that in 2020. world. As a result, the probability of MACE in COVID-variants of COVID-19 have been shown to be less viru-

ces, which might provide more mechanistic and therapeu-
tic insights. Tools to identify patients who are at risk of various complications and a poor prognosis are sorely needed, especially in a resource-limited setting. In the nomogram, the variables are all relatively inex-

pensive to measure. The clinical characteristics are read-
ily available within minutes, and the laboratory findings are easily obtained within hours. Thus, this nomogram could be used by physicians to predict the likelihood of MACE in hospitalized COVID-19 patients. High-risk patients might need earlier aggressive and individualized monitors, support and treatments, which are crucial for improving their prognosis. There were some differences in the C index in different sets and areas. The heteroge-
neties in the characteristics of the population and inci-
dence of MACE might be partly responsible for these results. It should be noted that the incidence of MACE in Sichuan Province was low. In addition, our nomo-
gram was developed and based on data collected at the beginning of 2020, during the 1st wave of the COVID-19 pandemic with the initial COVID-19 variant. Recently, variants of COVID-19 have been shown to be less viru-

lent and the vaccination rates are increased around the world. As a result, the probability of MACE in COVID-19 patients now is significantly lower than that in 2020. We admit that the predictive accuracy of nomogram could probably be decreased. However, we believe that the associations of these identified risk factors with development of MACE still exist in COVID-19 patients. Thus, our conclusions remain useful for decision making in clinical practice at present. However, considering the retrospective design, a small minority of incomplete baseline data and the heterogeneity of the composite endpoints, more large-scale, multicenter studies in dif-

erent epidemiological or environmental situations and genetic backgrounds are warranted to validate or update the prediction model before it can be used in clinical practice.

This study has several limitations. First, our study had unavoidable selection bias due to its retrospective observa-

tional nature. The sample size and number of patients with MACE were limited. We only included patients from two provinces in China without further external validation. Although our results have been validated in a distinct cohort, it is acknowledged that the model was derived from particular periods and places and it need to be updated or recalibrated as time goes on. Second, the results might have been affected by some confounders, including the drugs and therapies given before admis-

sion, the cardiovascular and renal comorbidities, and the heterogeneity of treatments among the different medical centers, which was especially significant at the beginning of the epidemic. We have tried to adjust for confounding factors in the multivariate analysis as much as possible, but our results still need more validation in the future. Third, we failed to conduct follow-ups or record cardio-

vascular events after discharge due to the scarcity of rela-
tive information. The long-term cardiovascular injuries caused by COVID-19 remain to be studied.

**Conclusions**

We developed and validated a nomogram that incorpo-

rated age, PaO2/FiO2 under 300, unconsciousness, lymphocyte counts, neutrophil counts and BUN to predict the development of MACE in hospitalized COVID-19 patients. The results of the C index, calibration curve and DCA showed the good performance and utility of the nomogram. It could empower front-line healthcare providers, inform decision-making, direct healthcare resources and improve patient prognosis. More pro-
spective multicenter studies are needed to confirm our results.

**Abbreviations**

MACE: Major adverse cardiovascular events; COVID-19: Coronavirus disease 2019; DCA: Decision curve analysis; BUN: Blood urea nitrogen; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; WHO: World Health Organization; SARS: Severe acute respiratory syndrome; MERS: Middle East respiratory syndrome; PT: Prothrombin time; STEMl: ST-segment elevation myocardial infarction; CRP: C reactive protein; EPV: Events per variable; RT-PCR: Reverse-transcription polymerase chain reaction; CT: Computed tomography; AMI: Acute myocardial infarction; MRR: Magnetic resonance imaging; SD: Standard deviation; IQR: Interquartile range; LASSO: Least absolute shrinkage and selection operator; OR: Odds ratio; 95% CI: 95% Confidence interval; PaO2/ FiO2: Arterial partial pressure of oxygen/fraction of inspiration oxygen; ACEII.
Angiotensin-converting enzyme type II; RAAS: Renin–angiotensin–aldosterone system; HR: Hazard ratio; NLR: Neutrophil lymphocyte ratio; AKI: Acute kidney injury; MD: Mean difference; NT-proBNP: N-terminal pro brain natriuretic peptide; MIS-C: Multisystem inflammatory syndrome in children.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12889-022-02143-3.

Additional file 1. Table S1. Comparisons of clinical baseline characteristics between training set and testing set. Figure S1. LASSO regression selection for MACE in training set. Figure S2. The calibration curve of nomogram in Wuhan subgroup. Figure S3. The DCA of nomogram in Wuhan subgroup. Figure S4. The calibration curve of nomogram in Sichuan subgroup. Figure S5. The DCA of nomogram in Sichuan subgroup.

Acknowledgements

Not applicable.

Author contributions

DH, H, Yang, H, Yu, TW, ZC, RY and ZL contributed to the conception and design. RY and ZL supervised the whole process. DH, H, Yang, H, Yu, TW and ZC contributed to data collection. DH and H, Yang analyzed and interpreted the patient data. DH and H, Yang wrote major parts of the manuscript. H, Yu, TW, ZC, RY and ZL revised the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the Emergency Response Project for New Coronavirus of Science and Technology Department of Sichuan Provincial (2020YFS0005 and 2020YFS0009).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This study was conducted in accordance with the Declaration of Helsinki and approved by the West China Hospital of Sichuan University Biomedical Research Ethics Committee (Approval Number 2020-272). West China Hospital of Sichuan University Biomedical Research Ethics Committee waived the need of informed consent due to the retrospective observational design.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, No 37 Guoxue Alley, Chengdu 610041, Sichuan, China. 2Department of Infectious Inpatient Ward Two, Chengdu Public Health Clinical Medical Center, Chengdu, Sichuan, China. 3Department of Emergency Medicine, Emergency Medical Laboratory, West China Hospital, Sichuan University, No 37 Guoxue Alley, Chengdu 610041, Sichuan, China. 4Disaster Medical Center, Sichuan University, Chengdu, Sichuan, China.

Received: 31 May 2021 Accepted: 8 September 2022

Published online: 12 September 2022

References

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
2. World Health Organization. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
3. COVID-19 Map—Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html.
4. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26(6):729–34.
5. AlSamman M, Caggiula A, Ganguli S, Misak M, Pourmand A. Non-respiratory presentations of COVID-19: a clinical review. Am J Emerg Med. 2020;38(11):2444–54.
6. Lodigiani C, Iapichino G, Carengo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14.
7. Hamadeh A, Aldjuej A, Briedi K, et al. Characteristics and outcomes in patients presenting with COVID-19 and ST-segment elevation myocardial infarction. Am J Cardiol. 2020;131:1–6.
8. Li Y, Li M, Wang M, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol. 2020;5(3):279–84.
9. Tan YY, Goh C, Leow AST, et al. COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. J Thromb Thrombolysis. 2020;50(3):587–95.
10. Collins GS, Reitms JA, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594.
11. Peduzzi P, Conrado J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373–9.
12. World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected: interim guidance. https://www.who.int/publications-detail clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 13 Mar 2020.
13. Sharma A, Pagidipati NJ, Calif IR, et al. Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes mellitus: lessons learned and future directions. Circulation. 2020;141(10):843–62.
14. Thyesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction. Circulation. 2018;138(20):e618–51.
15. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–236.
16. Caetano SJ, Sonpavde G, Pond GR. C-statistic: a brief explanation of its construction, interpretation and limitations. Eur J Cancer. 2018;80:130–2.
17. Iasonos A, Schrag D, Raj GV, Panagiotas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–70.
18. Alba AC, Agoritsas T, Walsh M, et al. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA. 2017;318(14):1377–84.
19. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak. 2006;26(6):565–74.
20. Zhu H, Rhee JW, Cheng P, et al. Cardiovascular complications in patients with COVID-19: consequences of viral toxicities and host immune response. Curr Cardiol Rep. 2020;22(5):32.
21. Dou Q, Wei X, Zhou K, Yang S, Jia P. Cardiovascular manifestations and mechanisms in patients with COVID-19: consequences of viral toxicities and host immune response models. Med Decis Mak. 2020;31(2):893–904.
22. Hendeen NS, Drazner MH, Bozkurt B, Cooper LT Jr. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020;141(23):1903–14.
23. Colling ME, Kangti Y. COVID-19-associated coagulopathy: an exploration of mechanisms. Vasc Med. 2020;25(3):471–8.
24. Liu Y, Mao B, Liang S, et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur Respir J. 2020;55(5):2001112. https://doi.org/10.1183/13993003.01112-2020.
25. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.

26. Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS ONE. 2020;15(11):e0241955.

27. Garg RK. Spectrum of neurological manifestations in Covid-19: a review. Neurol India. 2020;68(3):560–72.

28. Liang W, Liang H, Ou L, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180(8):1081–9.

29. Mikami T, Miyashita H, Yamada T, et al. Risk factors for mortality in patients with COVID-19 in New York City. J Gen Intern Med. 2020;1–10.

30. Núñez J, Miñana G, Bodí V, et al. Low lymphocyte count and cardiovascular diseases. Curr Med Chem. 2011;18(21):3226–33.

31. Lv Z, Wang W, Qiao B, et al. The prognostic value of general laboratory testing in patients with COVID-19. J Clin Lab Anal. 2020;23668.

32. Ghahramani S, Tabrizi R, Lankarani KB, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis. Eur J Med Res. 2020;25(1):30.

33. Nin N, Lorente JA, Soto L, et al. Acute kidney injury in critically ill patients with 2009 influenza A (H1N1) viral pneumonia: an observational study. Intensive Care Med. 2011;37(5):768–74.

34. Shao M, Li X, Liu F, Tian T, Luo J, Yang Y. Acute kidney injury is associated with severe infection and fatality in patients with COVID-19: a systematic review and meta-analysis of 40 studies and 24,527 patients. Pharmacol Res. 2020;161:105107.

35. Pareek M, Singh A, Vadlamani L, et al. Relation of cardiovascular risk factors to mortality and cardiovascular events in hospitalized patients with coronavirus disease 2019 (from the Yale COVID-19 Cardiovascular Registry). Am J Cardiol. 2021;146:99–106. https://doi.org/10.1016/j.amjcard.2021.01.029.

36. Henein MY, Mandoli GE, Pastore MC, et al. Biomarkers predict in-hospital major adverse cardiac events in COVID-19 patients: a multicenter international study. J Clin Med. 2021;10(24):5863. https://doi.org/10.3390/jcm10245863.

37. Tessitore E, Carballo D, Poncet A, et al. Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease. Open Heart. 2021;8(1):e001526. https://doi.org/10.1136/openhrt-2020-001526.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions

BMC